BioMarin Pharmaceutical

BMRNintermediary

BioMarin Pharmaceutical is a leader in rare-disease therapeutics with a portfolio of enzyme replacement therapies and the breakthrough growth drug Voxzogo for achondroplasia. Its Roctavian gene therapy for hemophilia A represents a one-time curative approach.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($2.8B)

静的データ（リアルタイム財務ロード中…）

Enzyme Replacement Therapies (45%)

Voxzogo (30%)

Roctavian & Other (15%)

Royalties & Collaborations (10%)

セグメント構成と主要顧客

製品詳細

Voxzogo (vosoritide)30%

C-type natriuretic peptide analog for achondroplasia in children

Roctavian (AAV gene therapy)10%

Gene therapy for severe hemophilia A

Enzyme Replacement Therapies45%

Naglazyme, Vimizim, and Palynziq for lysosomal storage disorders and PKU

サプライチェーン関係

競合他社

Regeneron Pharmaceuticals

Rare disease biologics

影響: Limited overlap in rare disease

Pfizer Inc.

Gene therapy platforms

影響: Competing in gene therapy

Novo Nordisk

Rare blood disorders

影響: Competing in hemophilia

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

BioMarin PharmaceuticalのAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

San Rafael, California, USA

設立

1997

従業員数

4,200+

ウェブサイト

biomarin.com

セクター概況 — 제약 / 바이오

セクターニュース